{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T13:42:29Z","timestamp":1777902149340,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T00:00:00Z","timestamp":1251936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,9,3]],"date-time":"2009-09-03T00:00:00Z","timestamp":1251936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Arch Allergy Immunol"],"abstract":"<jats:p>Sarcoidosis is a systemic granulomatous disorder of unknown origin. In respect to clinical and immunological characteristics, it is indistinguishable from berylliosis. As an approach to develop a murine model reflecting some aspects of sarcoidosis, we attempted to induce berylliosis in mice by treating inbred F1 mice (C57B16 \u00d7 DBA\/2) with 3 mg beryllium sulfate (BeSO&lt;sub&gt;4&lt;\/sub&gt;) per kg body weight intraperitoneally. Either pure BeSO&lt;sub&gt;4&lt;\/sub&gt; or BeSO&lt;sub&gt;4&lt;\/sub&gt; in combination with incomplete Freund\u2019s adjuvant was administered. Alternatively, pure BeSO&lt;sub&gt;4&lt;\/sub&gt; was injected 2 days after a single application of cyclophosphamide (150 mg\/kg). The spleen index, the spontaneous and phorbolmyristate acetate (PMA)-induced radical oxygen intermediates (ROI) released by peritoneal macrophages, and the proliferative activity of spleen mononuclear cells in response to BeSO&lt;sub&gt;4&lt;\/sub&gt; and concanavalin A (ConA) were evaluated and compared to the corresponding changes observed in sarcoidosis. In all three modes of BeSO&lt;sub&gt;4&lt;\/sub&gt; treatment, the spontaneous ROI release by peritoneal macrophages was significantly elevated. These elevations were very similar to those observed with alveolar macrophages in active sarcoid alveolitis. After BeSO&lt;sub&gt;4&lt;\/sub&gt; treatment, a small proliferative activity of spleen mononuclear cells in response to BeSO&lt;sub&gt;4&lt;\/sub&gt; could be observed. Further, BeSO&lt;sub&gt;4&lt;\/sub&gt;-treated spleen mononuclear cells exhibited a markedly reduced response to ConA stimulation (\u224820% of control) which parallels the reduced proliferative capacity of sarcoid peripheral blood mononuclear cells (\u224845% of control). This reduction could be abolished by pretreating the mice with cyclophosphamide. BeSO&lt;sub&gt;4&lt;\/sub&gt; treatment in combination with incomplete Freund\u2019s adjuvant resulted in a significant increase of spleen mononuclear cell proliferation (1.9-fold) after in vitro stimulation with BeSO&lt;sub&gt;4&lt;\/sub&gt;, and prevented the low responsiveness to ConA. All these findings were maximal after 2 and vanished after 5 weeks. In conclusion, BeSO&lt;sub&gt;4&lt;\/sub&gt; treatment of mice yields immunological disturbances which parallel some immunopathological phenomena of patients with sarcoidosis.<\/jats:p>","DOI":"10.1159\/000236688","type":"journal-article","created":{"date-parts":[[2009,9,4]],"date-time":"2009-09-04T09:04:16Z","timestamp":1252055056000},"page":"332-339","source":"Crossref","is-referenced-by-count":2,"title":["Beryllium-Induced Disturbances of the Murine Immune System Reflect Some Phenomena Observed in Sarcoidosis"],"prefix":"10.1159","author":[{"given":"Sibylle","family":"Pfeifer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"Strausz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Haller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"M\u00fcller-Quernheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,9,3]]},"container-title":["International Archives of Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/236688","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000236688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:21:21Z","timestamp":1777634481000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000236688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,3]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000236688","archive":["Portico"],"relation":{},"ISSN":["1018-2438","1423-0097"],"issn-type":[{"value":"1018-2438","type":"print"},{"value":"1423-0097","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,3]]}}}